scieee AI-readable full text Open interactive document viewer

Current state-of-the-art review of nanotechnology-based therapeutics for viral pandemics: Special attention to COVID-19

Motiei, Marjan,Lucia, Lucian A.,Sáha, Tomáš,Sáha, Petr

Abstract

RP/CPS/2022/005; Ministerstvo Školství, Mládeže a Tělovýchovy, MŠMT

Full text

Review Article Marjan Motiei*, Lucian A. Lucia, Tomas Sáha, and Petr Sáha Current state-of-the-art review of nanotechnology-based therapeutics for viral pandemics: Special attention to COVID-19 https://doi.org/10.1515/ntrev-2022-0515 received October 11, 2022; accepted January 16, 2023 Abstract: Over the past two centuries, most pandemics have been caused by zoonotic RNA viruses with high mutation, infection, and transmission rates. Due to the importance of understanding the viruses’role in establishing the latest outbreak pandemics, we briefly discuss their etiology, symptomatology, and epidemiology and then pay close attention to the latest chronic communicable disease, SARS-CoV-2. To date, there are no generally proven effective techniques in the diagnosis, treatment, and spread strategy of viral diseases, so there is a profound need to discover efficient technologies to address these issues. Nanotechnology can be a promising approach for designing more functional and potent therapeutics against coronavirus disease 2019 (COVID-19)and other viral diseases. Moreover, this review intends to summarize examples of nanostructures that play a role in preventing, diagnosing, and treating COVID-19 and be a comprehensive and helpful review by covering notable and vital applications of nanotechnology-based strategies for improving health and environmental sanitation. Keywords: viral pandemics, nanotechnology, prevention, diagnosis, treatment Abbreviations Alum Aluminum hydroxide ACE2 Angiotensin-converting enzyme II CDs Carbon dots CNTs Carbon nanotubes CTD Carboxy-terminal domain CS Chitosan COVID-19 Coronavirus disease 2019 EWNS Engineered water nanostructures G Graphene GO Graphene oxide HA Hemagglutinin HSPG Heparan sulfate proteoglycan HEK Human embryonic kidney HIV Human immunodeficiency virus IPC Infection prevention and control IAV Influenza A virus IVM Ivermectin KGM Konjac glucomannan  * Corresponding author: Marjan Motiei, Centre of Polymer Systems, Tomas Bata University in Zlín, Třída Tomáše Bati 5678, 76001 Zlín, Czech Republic, e-mail: [email protected] Lucian A. Lucia: Departments of Forest Biomaterials, Chemistry, Campus Boxes 8005, 8204, North Carolina State University, Raleigh, North Carolina 27695, United States of America; State Key Laboratory of Bio-based Materials & Green Papermaking, Qilu University of Technology/Shandong Academy of Sciences, Jinan 250353, China Tomas Sáha: University Institute, Tomas Bata University, Zlin 76001, Czech Republic Petr Sáha: Centre of Polymer Systems, Tomas Bata University in Zlín, Třída Tomáše Bati 5678, 76001 Zlín, Czech Republic; University Institute, Tomas Bata University, Zlin 76001, Czech Republic Graphical abstract: Nanotechnology is a promising approach for preventing, diagnosing, and treating COVID-19 and related viral diseases. Nanotechnology Reviews 2023; 12: 20220515 Open Access. © 2023 the author(s), published by De Gruyter. This work is licensed under the Creative Commons Attribution 4.0 International License. LFIA Lateral flow immunoassay LNPs Lipid NPs Mal Maleimide MERS-CoV Middle east respiratory syndrome coronavirus MWCNTs Multi-walled carbon nanotubes NP Nanoparticle NTD Amino-terminal domain HTCC N-(2-hydroxypropyl)-3-trimethylammo- nium chitosan chloride NA Neuraminidase ORFs Open reading frames PPE Personal protective equipment PF Phenol-formaldehyde PEG Poly(ethylene glycol) PEI Poly(ethyleneimine) PDMS Poly(dimethylsiloxane) PLA Poly(lactic acid) PLGA Poly(lactic-co-glycolic) PMMA Poly(methylmethacrylate) PP Polypropylene PS Polystyrene PVA Poly(vinyl alcohol) PVDF Poly(vinylidene fluoride) RBD Receptor-binding domain Rha(s)Rhamnolipids RT-PCR Reverse transcription polymerase chain reaction SARS Severe acute respiratory syndrome SARS-CoV Severe acute respiratory syndrome coronavirus SA Sialic acid ssRNA Single-stranded RNA SERS Surface-enhanced Raman scattering TMB Tetramethylbenzidine UV Ultraviolet UTR Untranslated region 1 Introduction A pandemic is an epidemic in which the vector contagion spreads globally. Despite technological developments, pandemics have been prevalent during the last two centuries. Except for the sixth cholera pandemic (1910–1911) that originated by a bacterium (Vibrio cholera), most pandemics have been caused by zoonotic RNA viruses [1]. These RNA viruses demonstrate high pandemic potential owing to the lack of a proofreader. Therefore, they show higher mutation rates than the DNA varieties and are Table 1: Different virus pandemics that have spread globally and continue to this day (since 1918) Pandemic Virus Years of activity Country of origin Animal vector Global mortality rate (in millions) Average mortality age Spanish Flu A/H1N1 1918–1920 Spain Avian 50 Very young, elderly, and healthy young adults aged 20–40 Asian Flu A/H2N2 1956–1958 China Avian 1–2 School-age children and young adults aged 35–40 Hong Kong Flu A/H3N2 1968–1970 Hong Kong Avian 0.5–262–65 AIDS HIV/AIDS 1981–Present Democratic Republic of the Congo Chimpanzee 36 Males about 50.8 years, and females about 49.7 years reported in 2013. http://www.cdc.gov/nchs/data_access/ vitalstatsonline.htm. Swine Flu A/H1N1 2009–2010 Mexico Pigs 0.148–0.249 37 COVID-19 SARS- CoV-2 2019–Present China Bats, pangolins? 5.7 through February 2022 0.02% in age of 20–49, 0.5% age of 50–69, and greater than 5.4% in age of more than 80 2Marjan Motiei et al. more adaptable to human infection and transmission. The other concerning situation is spreading through respiratory droplets, which transmit from person to person through close interactions [2]. According to Table 1, most of these pandemics are attributed to contagious respiratory illnesses induced by influenza viruses and coronaviruses, while the other is an acquired immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV)affecting thereproductivetract,theurinarytract,andthedigestive tract (oral cavity, anus, and rectum). Herein, we brieflycompare these three zoonotic RNA viruses epidemiologically and then focus on various strategies to prevent, diagnose, and treat the latest chronic communicable disease, which can also be applicable in other virus-induced diseases. 1.1 AIDS The virus causing HIV belongs to the Retroviridae family with a diameter ∼100 nm. Two major types of HIV are: HIV-1(the most common and responsible for over 95% of all infections)and HIV-2(relatively uncommon and less infectious). The spherical HIV-1 virion contains two copies of (+)ssRNA genome and replicative enzymes surrounded by a membrane containing HIV-1 envelope glycoprotein (Figure 1a). This sole antigen is a homotrimeric protein post-translationally cleaved into gp41, the transmembrane domain that constitutes the protein’s fusion peptide, and gp120, a surface domain that mediates receptor binding [3]. The binding of HIV-1 envelope glycoprotein to the CD4 + T cells induces conformational changes in the glycoprotein and subsequent interaction with chemokine co-receptors such as CCR5 and CXCR4 to facilitate active transport processes. Afterwards, in the presence of enzymatic machinery, RNA transforms into DNA in the host cell’s cytoplasm and subsequently integrates into the cell genome. Consequently, chronic disease is a result of strong antibody responses, which can progress to AIDS [4,5]. HIV transmission mechanism: Direct contact of the infected patient’s biofluids (i.e., blood, breast milk, male and female sexual fluids)with the specific mucosa or bloodstream of the other person lead to HIV-1 transmission [4]. Therefore, transmission mechanisms are categorized according to three routes: sexual, parenteral, and vertical. Sexual transmission occurs with a high concentration of HIV-1 in the genital tract with a higher transmission risk for females [6]. Parenteral transmission occurs after biofluids’contact subcutaneously, intramuscularly, or intravenously [7]. Finally, vertical transmission is defined as mother-to-child-transmission, which occurs via three different routes, including utero, intrapartum, and breastfeeding [8]. HIV symptomatology: The symptoms appear as an acute infection within the first two months and chronic infection following the next six months. In the acute phase, infected people present swollen lymph nodes, fever, headache, rashes, and pains in the muscles, throat, and mouth. In the chronic phase, immunosuppression happens, and AIDS, with many life-threatening diseases, occurs in an untreated infection [4]. Figure 1: Schematic representation showing the structure of: (a)HIV, (b)IAVs, and (c)SARS-CoV-2. SARS-COV-2 and nanotechnology 3 HIV therapeutics and treatment: Aprima facie treatment goal is to limit viral transmission by reducing the viral load in biofluids. Therapeutic vaccination is the most cost-effective, non-invasive, promising strategy for long-lasting immunity [9]. Passive antibody administration, latency reversal agents, adjuvants, and immune modulators are known to enhance vaccine potency [10]. Histone deacetylase inhibitor romidepsin [11], two major categories of Integrase Inhibitors, and single drug molecule with dual inhibitor activity against integrase and reverse transcriptase are among a suite of promising therapeutics [8]. 1.2 Influenza (Flu) Influenza viruses with A, B, C, and D subtypes belong to the Orthomyxoviridae family. They possess ∼150–200 nm diameters with roughly spherical to pleomorphic and filamentous shapes. The envelope is a host-derived lipid bilayer, where the spikes are radiated outward [12]. They have seven or eight (−)ssRNA genome encoding structural and non-structural proteins. Influenza A viruses (IAVs)are the only ones with a pandemic potential (Table 1).IAVs have eight single-stranded viral RNA segments in separate viral ribonucleoprotein (RNP)complexes packaged into a single virus particle (Figure 1b). The structure of viral RNA plays an essential role in directing gene reassortment between human IAVs and animal reservoirs, which led to the emergence of pandemic subtypes [13]. There are different IVAs based on the rod-shaped spikes of hemagglutinin (HA)and mushroom-shaped spikes of neuraminidase (NA). HAs encoded by 1–16 genes and NAs encoded by 1–9 genes are involved in viral attachment and release, which happens at various pH and times during the virus life cycle [12]. Of the 144 total combinatorial possibilities, only four combinations of HAs and NAs (H1N1, H2N2, H3N2, and possibly H3N8)cause pandemics owing to partial or lacking immunity in the human genome [1]. Transmission mechanism: The most important routes of IVA transmission are via contact (i.e., direct, indirect, and droplet), air, or a combination. Direct contact occurs via direct physical contact between an infected patient and a susceptible host). Indirect contact occurs by passive transfer of IVA to a susceptible host via contaminated hands, instruments, or other intermediate objects. Large droplets (≥5µm diameter) generated from the respiratory tract of a colonized individual is the other way of contact transmission. Finally, airborne transmission via aerosols can occur over airborne particles less than 5 µm or dust particles containing IVA [14]. Symptomatology: Typical upper respiratory tract infection symptoms include fever and chills, nonproductive cough, rhinitis, muscle pain, and sore throat. In most people, these symptoms, except cough and malaise, resolve after 3–7 days, which can continue for more than 2 weeks, primarily in elder and chronic lung infected individuals. In severe disease, otitis media, respiratory, cardiac, musculoskeletal, and neurologic complications may occur [15]. Influenza therapeutics and treatment: The main treatment goal reduction of the viral load by diminishing viral replication. The treatment is initiated by prescription of NA inhibitors (oseltamivir)plus fibrates (fenofibrate). Due to virus NA mutations, Fludase (a recombinant sialidase fusion protein), Nitazoxanide (a novel thiazolide that inhibits IVA replication), and Favipiravir may cover resistant influenza strains. Corticosteroids are the other common drug, which may not be ideal for influenza viral infections [16]. 1.3 Severe acute respiratory syndrome (SARS) The life-threatening respiratory infection, SARS, is driven by an important species of the Coronaviridae family, SARS-associated coronavirus. The four genera of these coronaviruses are alpha,beta,delta, and gamma [17]. While alpha and beta originate from mammals, in particular particularly bats, gamma and delta originate from pigs and birds [18]. The enveloped (+)ssRNA viruses encode structural and non-structural proteins. Proteins of the membrane, spike, envelope, and nucleocapsid are the four main structural proteins [1]. Among the seven subtypes that infect humans, alpha‐coronaviruses (i.e., HCoV-229E and HCoV-OC43)cause asymptomatic or mildly symptomatic infections [1,18].Whereasbeta-coronavirus subgenuses lead to diseases with varying degrees of infectious potential, including lower respiratory tract infection through HCoV-NL63 and HCoV-HKU1, severe pneumonia through SARS-CoV, middle east respiratory syndrome coronavirus (MERS-CoV),andfinally SARS-CoV-2[1]. Table 2 describes the epidemiological characteristics of SARS infections. Infectious bronchitis virus is a gammacoronavirus that produces highly contagious disease in chickens, especially in the reproductive and upper respiratory tracts [17]. However, different delta-coronavirus species have not caused disease in wild birds; a sickness in farmed quail in Poland and psittacine proventricular dilatation disease in green-cheeked Amazon parrot are attributed to delta-coronavirus [19]. Herein, we focus on 4Marjan Motiei et al. SARS-CoV-2 properties, transmission mechanisms, and symptomatologies. 1.3.1 SARS-CoV-2 This subgenus of beta-coronavirus shows a high sequence identity as a Bat beta-coronavirus [4,17].Thevirionsizeis around 70−90 nm, whose complete genomic sequence shows a high genetic similarity with other subtypes inducing respiratory infections [4]. The genome is encapsulated by a protein-based capsid covered by a phospholipid bilayer membrane (Figure 1c). The membrane is essential for virus-cell fusion through the binding of the spike protein and cellular angiotensin-converting enzyme II (ACE2) of the target tissues (i.e., lung, cardiovascular system, intestine, and kidney)[20]. After releasing the viral genome containing 6–20 open reading frames (ORFs)into the host cytoplasm, ORF1a/b is translated into two structural and 16 nonstructural proteins to assemble into replication–transcription complexes. The complexes within double-membrane vesicles synthesize sets of genomic and subgenomic RNAs that encode several structural and accessory proteins. The newly formed RNAs, nucleocapsid, and envelope proteins bud from the endoplasmic reticulum-Golgi apparatus and merge with the cell membrane to form new viral particles [4]. The viruses have demonstrated different mutations, especially on spike protein, which led to further variants with different transmission rates, reinfection risk, disease severity, and treatment [21]. This trimeric glycoprotein containstwodomainsofS1andS2.TheexposedS1domainisin amorevariablemodethanthepartiallyburiedS2domain. The main parts of S1 also include the receptor-binding domain (RBD),amino-terminal domain (NTD),andcarboxy-terminal domain (CTD), which the RBD and the NTD show more variability than CTD [21]. The variability leads to many variants, as described in Table 3. According to the WHO, in April 2022, delta and omicron are categorized in variants of concern, and the others as variants of interest. SARS-CoV-2 transmission mechanism: It may be transferred directly by human biofluids and indirectly by the environment (i.e., waters, foods, and many surfaces) [4,37]. The primary transmissionmethodsarethroughaerosols with a particle diameter of <5µm during respiration, vocalism, or the solid residual particles after the droplet vaporization [38]. There is no report on SARS-CoV-2infec- tion transmission via food, but it should be mentioned that CoVs may survive at 4°C up to 2–4daysonfreshfood[39]. According to WHO, the risk of fecal transmission seems to be low. However, feces may be a reason of hands, water, food contaminations [40], and coronavirus disease 2019 (COVID-19)transmission through fecal–oral, fecal–fomite, or fecal–aerosol [41,42]. SARS-CoV-2 symptomatology: Most cases reveal mild symptoms such as fever, cough, dyspnea, diarrhea, and abdominal pain 2–14 days after exposure. Nonetheless, most severe cases show progressive respiratory failure and even death [4]. 2 Nanotechnology for prevention, diagnosis, and treatment Infection prevention and control (IPC)relies on a thorough understanding of the factors that affect transmission [43]. To implement IPC, nanotechnology is a discipline that offers scientific and practical approaches to the prevention, diagnosis, and treatment of infectious illnesses. In the case of prevention, nano-sized vaccines mimic the virus without any replicated genome, replaceable nanoporous membrane for N95 face masks, applying self-disinfecting nanocoatings for air filters, and using nano-disinfectants in the environment are examples of nanotechnology in the prevention of virus spread [44]. Nanodiagnostics also rely on combining nanoparticles (NPs)with target molecules to produce a measurable signal for detection. In this technology, the nanoscale Table 2: The epidemiological characteristics of SARS infections SARS-CoV epidemic MERS-CoV epidemic SARS-CoV-2 pandemic Common symptoms Influenza-like syndrome with dry cough, fever, malaise, body aches and pains, diarrhea Cough, fever, breathlessness, and even gastrointestinal issues Cough, fever, breathlessness, loss of taste or smell, potential gastrointestinal issues Years 2002–2003 2015–present 2019–present Potential animal reservoirs Bats Bats Bats, pangolins Intermediary hosts Palm civets Dromedary camels Not identified yet Origin Guangdong province (China)Jeddah (Saudi Arabia)Wuhan (China) SARS-COV-2 and nanotechnology 5 Table 3: Different SARS-CoV-2 mutations and variations along with their epidemiology Variant Lineage Origin Date Mutations Transmissibility Severity Ref. Epsilon B.1.427 California March 2020 Spike mutations: RBD, NTD, CTD, signal peptide 18.6–24% more than the wildtype strains No evidence [22] B.1.429 Zeta P.2 (B.1.1.28.2)Brazil April 2020 Spike mutations: RBD, CTD Increase 23% No evidence [23] Beta B.1.351 South Africa May 2020 Spike mutations: RBD, NTD deletion 50% more than the previously circulating variants High [24] Alpha B.1.1.7 UK September 2020 Spike mutations: RBD, NTD deletions Highest with a 50–100% reproduction rate High with 50% increased mortality [25,26] Non-spike mutations: nucleocapsid, p6:Δ106–108, Delta B.1.617.2 India October 2020 Spike mutations: RBD, NTD, CTD, S2, proximal furin cleavage site More than the alpha High [27,28] Non-spike mutations: orf3, orf7a, orf1a/b, and Nucleocapsid gene Kappa B.1.167.1 India October 2020 Spike mutations: RBD, NTD, S2, proximal furin cleavage site High but less than delta No evidence [29] Non-spike mutations: orf3, orf7a, orf1a/b, Nucleocapsid gene Gamma P.1 (B.1.1.28.1)Brazil November 2020 Spike mutations: RBD, Five NTD mutations High High [30] Iota B.1.526 New York November 2020 Spike mutations: RBD, NTD, CTD, signal peptide, Near the furin cleavage site High High [31] Non-spike mutations: T85I, L438P, 9 bp deletion Δ106- 108, P323L, Q88H, Q57H, P199L and M234I Eta B.1.525 Nigeria December 2020 Spike mutations: RBD Lower than Alpha variant High [32] Lambda C.37 Peru December 2020 Spike mutations: RBD, NTD deletion No evidence No evidence [33] Theta P.3 Philippines January 2021 Spike mutations: RBD, NTD deletion, CTD High No evidence [34] Mu B.1.621 Colombia January 2021 Spike protein: RBD, NTD, CTD, S2 region High No evidence [35] Omicron B.1.1.529 Multiple countries November 2021 Spike mutations: RBD, NTD, CTD, fusion peptide, heptad repeat 1, proximal to the S1/S2 cleavage site, S2 protein High Low [36] 6Marjan Motiei et al. procedures lead to handheld devices that are stable, highly sensitive, and marketable [44,45]. Finally, nanotechnology-based approaches can be a promising tool to enhance the potency and selectivity of physical, chemical, and biological therapies with minimized toxicity to normal cells. Targeted NPs have been designed to deliver lethal doses of therapeutics actively or passively to pathogenic cells [46]. This nanotechnology in COVID-19 mainly focuses on disrupting the cell receptor ACE2 interaction through different approaches, including recombinant ACE2, antibodies, and protease inhibitors to scavenge the virus, interfering with the spike/ACE2 interaction, and inhibit the spike protein processing, respectively [20]. 2.1 Prevention The SARS-CoV-2 virion is primarily transmitted by air spreading to the entire respiratory system of the human body. Afterwards, the virion is functionally larger due to the presence of other airway materials (i.e., bacterial cells and epithelial cells)in the liquid droplets of the respiratory tract. The large droplets (>150 µm)show a low evaporation rate, which affects the aerosolized virus survival, transport, and fate. This virion is stable at RT and 4°C but inactivated under ultraviolet (UV)light and extreme pH conditions (pH >12 and pH <3), and heating at 65°C for 5 min [20]. Considering transmission, COVID-19 spreading should be controlled personally and environmentally. According to Figure 2, maintaining vaccination, personal protective equipment (PPE), and environmental sanitation are practical ways that lead to widespread community-level protection [47]. This section outlines the potential applications of nanotechnology for reducing infection risks to people, with a specificfocusonseveralindividual and environmental factors. Recent studies using NPs for infection prevention are shown in Table 4. 2.1.1 Vaccines Despite a lengthy and complicated vaccination procedure in resolving the pandemic outbreak, it is highly effective. An effective vaccine is composed of antigens, adjuvants, immune enhancers, and delivery systems, which activates the immune system by generating neutralizing antibodies and T cells [48]. Many trials have been done to develop an effective vaccine that targets full-length spike protein or RBDs [49]. Currently, conventional vaccine production platforms include inactivated virus, live-atte- nuated, subunit-based, viral vector-based, and DNA/mRNA vaccines [47,49]. Although inactivated and live-attenuated vaccines have a rapid manufacturing process, the live-atte- nuated vaccine is innately immunogenic by affecting the toll-like receptors and may recover virulence. Nonetheless, inactivated vaccines are more stable and safer than liveattenuated vaccines; the antigens may be destroyed during inactivation [43,47].Beijing-based Sinovac Biotech (NCT04383574, NCT04352608)is one of the groups that developed the inactivated vaccines [20]. Subunit vaccines are recombinant spike proteins with low immunogenicity, Figure 2: Schematic illustration for infection prevention against COVID-19. SARS-COV-2 and nanotechnology 7 immunological memory, and stability but high safety and low side effects [47,49]. Adjuvants might be added to increase immunogenicity and reduce the number of vaccine cargos per dose [49]. Novavax (NCT04368988)developed a subunit vaccine containing an adjuvant named saponin-based Matrix M[20]. Viral vector-,DNA-,andRNA-based vaccines are gene delivery systems to trigger a vigorous immune response. Due to their intrinsic adjuvant activity, non-replicable viral vectors have a strong immune-stimulating effect [49]. The University of Oxford/AstraZeneca is one of the groups that developed adenoviral vector vaccines to produce the SARS-CoV-2 spike protein [20]. Another member of the genetic vaccine is the DNA vaccine. However, the synthetic DNA vaccine is thermostable and shows lower titers of antibodies than other vaccination strategies, and viral genome integration into the host DNA may lead to cancer. A DNA plasmid vaccine developed by Inovio Pharmaceuticals (INO-4800)is currently undergoing human Phase I testing (NCT04336410)[20]. The RNA vaccine contains mRNAs or siRNAs that switch offcrucial target genes or synthesize vital virus proteins [20]. However, effective RNA delivery to the target is challenging because of the thermosensitivity of RNA, insertional mutagenesis risk, and antivector immunity [47]; they can elicit high levels of neutralizing mAbs and memory B cells and broaden the response to different variants [21]. Nanomaterials have already played key roles in vaccine delivery systems due to their stability, immunity, and delivery [20]. The relatively safe NP-based vaccines present antigens in their original forms [50]and stimulate antigen-specific immune responses even without adjuvant [51]. These nanovaccines can intrinsically or extrinsically activate the immune system because of functionalization or antigenic cargos. Biocompatible lipid, protein, polymer, carbon-based, and inorganic NPs can encapsulate antigenic cargo with high loading efficiency and improve pharmacokinetics. Major NP platforms are lipid NPs (LNPs)and protein NPs. LNPs, containing ionizable lipids, demonstrate strong potential as a gene delivery system with high loading capacity, transfection efficiency, and endosomal escaping to stabilize and protect them from degradation [43]. In two studies, LNPs were utilized for mRNA delivery of RBD [52]and full-length spike protein [53]. The current US FDA-approved mRNA-based LNP vaccines are BNT162b2 and mRNA-1273, developed by Pfizer/BioNTech and Moderna, respectively [54–56].To improve the real-world effectiveness of the vaccine, alphaviral replicase was added to the RNA sequences and replaced the mRNA’s untranslated region (UTR)with a synthetic UTR to self-amplify the RNA and increase protein Table 4: A semi-exhaustive list of selected NPs for infection prevention against COVID-19 Organic NPs Inorganic NPs Inorganic/organic NPs LNPs Protein NPs Polymer NPs Carbon-based NPs Vaccination mRNA of RBD/ LNPs [52], Spike protein/LNPs [53] Spike protein/ferritin [64], RBDs/ferritin [65,67], RBD/ aldolases [62,63] DNA/PLA [84]Recombinant peptidemodified nanodiamonds [97] Spike protein/silica NPs [93]mRNA-1273/PEGylated lipids [86] PPE nano-micelles of Rha(s)[99] —Synthetic polymers/ oligomers [100], licorice roots extract/ PVA [101] G[102], polydopamine/ GO [103] Zn [104],Cu[105], Ag NPs [106], MOFs/Cu/Zn [107],Ag nanocluster/silica composite [108] TiO 2 nanotubes/CS/PVA, CS/PVA, and silk/PVA [109], shellac/CuNPs [110], PVDF/PS nanofibers/Ag/Zn coated cotton [111] Water and wastewater Treatment —— CS [112]CNTs/GO/PP [113]Cu/TiO 2 nanofibers [114]TiO 2 /G nanohybrid materials [115] Air purification —— PMMA/PDMS/CS [116]Laser-induced G [117], MWCNTs/PF [118] Ag NPs [119], AgNP/SiO 2 hybrid particles [120], Ag/ Al 2 O 3 and Cu/Al 2 O 3 [121] nano-Ag/TiO 2 /CS [122], TiO 2 /crystal violet nanocomposites [123], ZnO NPs/ PVA/KGM [124], nano-Ag/TiO 2 /CS [122] Surface disinfection —— CS [125]—TiO 2 [126], AgNPs [127], silica [128] AgNPs/cellulose [129],Cu 2 O/ polyurethane [130] 8Marjan Motiei et al. translation, respectively [49]. There are also adjuvantencapsulated LNPs such as QS-21 included in the liposomes decorated with RBDs [57]and alum-packed on the squalene [58],whicheffectively activates the humoral and cellular immune system. Protein-based NPs are constructed through self-assem- bling monomers, which are subsequently covalently or noncovalently bound to viral antigens [43].Theseantigen-pre- senting NPs imitate the viral structure and elicit potent immune responses, which are helpful in reducing the immunogenicity of protein-based vaccines [59]. Popular proteinsforvaccinesareferritin[60,61]and aldolase [62,63]. Recently, full-length spike protein/ferritin [64], RBDs/ferritin [65],RBD-24-mer/ferritin [66],andRBD/ aldolases [62,63]were generated as a possible vaccine against the virus. Ma et al. conjugated RBD and/or heptad repeat to the 24-mer ferritin to induce humoral and cellular immune responses [67]. Ferritin can self-assemble into octahedral particles with three-fold axes and present multiple ordered viral antigens on the particle surface [68]. Scientists have also designed nanomer peptide vaccines using a new strategy, immunoinformatics, to map and identify epitopes in the SARS-CoV-2 protein sequences [69]. Sahoo et al. predicted SARS-CoV-2 nanomer epitopes for T-cell against class I and II of major histocompatibility complex, which may serve as sensitive, rapid, and cost effective vaccines [70]. Protein-based NPs can also be created with manufactured nanocomponents with adjuvant characteristics to induce immune responses [20]. Natural and synthetic polymers (Figure 3)have also been explored to prepare nanovaccines due to higher immunogenicity, biodegradability, biocompatibility, and a large surface area for targeting [71]. They are specifically developed in local and topical medications by considering their positive zeta potential to show higher immune stimulations and lower poly(ethylene glycol)(PEG)concentration to decrease the barriers [49]. These polymeric NPs, as carriers or adjuvants, can induce remarkable anti-inflam- matory, antibody, and T-cell cross-reactivity responses. Chitosan (CS)[72,73], trimethyl CS/hyaluronic acid [74], β-cyclodextrin/CS [75],alginate/CS[76], dextran [77],pullulan [78], and inulin [79]are examples of natural polymers utilized in vaccine delivery systems. Chitosan NPs (CSNPs) have been extensively studied in vaccine area owing to their biodegradability, biocompatibility, lack of toxicity, and ease of shape and size processing [80].Tailor-made polymers also offer certain advantages such as reproducibility in chemical, biological, mechanical, and interfacial properties [71]. They are mainly poly(lactic-co-glycolic)(PLGA)[81],poly(ϵcaprolactone)[82], dendrimers [83],poly(lactic acid)(PLA) [84], polyanhydride [85],andPEG[86].Amongthesesynthetic polymers, PLGA and PLA consider major synthetic polymers for mucosal antigen delivery [87].Biopolymers asadjuvantscanbeconjugatedwithvariousantigensfor Figure 3: Few examples of natural and synthetic polymers. SARS-COV-2 and nanotechnology 9 porcine reproductive and respiratory syndrome virus through inhibition of proliferation, stimulation of innate immune responses, and inhibition of ROS accumulation [194]. Various polymeric compounds have antiviral activity, which comprises polymer length, hydrophilicity, and charge [20]. In nucleic acid polymers, phosphorothioated oligonucleotides were utilized to inhibit the entrance of hepatitis B and hepatitis D viruses and HBsAg release against hepatitis Bvirus[214]. In polysaccharides, negatively charged polymersareperhapsthemostwidelystudied,whichshowa broad-spectrum antiviral effect on a variety of viruses. Alginate is an example of a negatively charged polysaccharide that shows antiviral activity due to the charge and phenolic structure [189]. Sulfated compounds with antiviral properties, including sulfated glyco-oligomers and glyco-polymers [190],Fucoidan-mimetic sulfated glycopolymers [215],PS sulfonate, PVA sulfate, polymethylene hydroquinone sulfonate, naphthalene sulfonate [214], dextran sulfate [216], heparan sulfate [190,217,218], dendritic polyglycerol sulfate [219],andcarrageenan[190,220–222]are attributed to length and sulfate content. For instance, heparin sulfate blocks the non-specific cell surface adsorption by preventing membrane fusion and interaction with viral glycoproteins [190]. Moreover, NPs decorated by heparan sulfate proteoglycan (HSPG)or sialic acid (SA)mimics demonstrated in vitro capacity to target most known respiratory viruses through binding to the attachment ligand of viruses and block their interaction with cell membranes [20]. Polymers modified by SA derivatives also exhibited antiviral activity due to the binding of virus HA to terminal sialic acid residues on cellular glycoproteins and glycolipids. So, Günther et al. worked on glycosylated dendritic polymers with 3′-sialyl- lactose and 6′-sialyllactose and confirmed that higher valency and spacing between ligands resulted in higher antiviral activity [191]. Positively charged polymers such as CS and its derivatives can also activate innate immune responses by upregulation of cytokines and chemokines, essential for preventing viral replication. Indeed, Zheng et al. demonstrated that pulmonary delivery of CS could induce widespread immune responses against the H7N9 influenza virus by increasing the number of macrophages, dendritic cells, and innate lymphoid cells [223]. PEG exhibits more near-neutral ζ-potential, and mPEG is synthesized by the replacement of the CH 3 moiety to the OH group of PEG. According to Kyluik et al., PEGylation of viruses with short-chain polymers can prevent infecting and invading viruses. In contrast,largechainpolymersprovide superior protection when grafted to host cells [224].Topermanently deactivate SARS-CoV-2, Cai et al. also reported aphotothermalcore–shell NP made of a semiconducting polymer and PEG functionalized with neutralizing antibodies [225]. The promising activity of the PEG polymer toward virusesisduetoitswatersolubility[226], and high PEGylation of NPs may cause extended systemic circulation half-life [49]. Moreover, NPs made of antiviral polymers can affect viral infectivity by eradicating the virus effectively [20]. 2.3.2 NPs as antiviral drug carriers NPs are attractive controlled-release systems to deliver single conventional therapeutics (i.e., hydrophobic/hydrophilic small molecules and macromolecules)or synergistic delivery of multiple therapeutics to the target. Apart from lowering systemic toxicity and immunogenicity in normal tissues, NPs can offer unique characteristics to the therapeutics, including solubilization, bioavailability improvement, release prolongation, protection against harsh environments, and targeting passively and/or actively [227]. Effectiveness of passive and active targeting is influenced by the physical characteristics of NPs, including charge, hydrophilicity, size, functional groups, and the conjugated moiety on the surface [228]. Targeted NPs lead to higher cellular uptake in target cells and then drug release at the site of action [227]. Several NPs were proposed as promising drug delivery systems categorized as inorganic and organic NPs. The inorganic NPs with antiviral properties are promising drug delivery systems to the target site. Chloroquine andhydroxychloroquinewereloadedontometalNPsby Morad et al., who concluded that these nanostructures would be an appropriate candidate for COVID-19 treatment [200]. Silica NPs are the other inorganic NPs utilized for the delivery of polyphosphate. Polyphosphate was released gradually at the site, bound to the viral RBD electrostatically, and prevented further interaction between spike protein and host receptor [201]. LNPs, as organic NPs, can encapsulate macromolecules like mRNAs for SARS-CoV-2 suppression. For rapid ACE2 expression, which can compete with endogenous ACE2 in virus suppression, mRNA was encapsulated in βsitosterol-doped LNPs. The mRNA can overcome limited half-life of recombinant ACE2 [196]. The antiviral potency of polymeric NPs can be enhanced by targeting and prolonging the controlled release of drugs. Targeted PLGA- b-PEG-maleimide (Mal)by an Fc immunoglobulin fragment was one of the polymeric NPs utilized to deliver hydrophobic ivermectin (IVM)and accumulate at the lung epithelia [198]. Nie et al. also noted that IAV virions bind significantly better to spiky NPs with 5–10 nm tall spikes. They predicted that cellular membrane coating and topography that matches geometry might develop nano-inhibitors for SARS-CoV-2[229]. 16 Marjan Motiei et al. The other strategy for viral targeting and neutralization is coating polymer NPs with the cell membrane [199]or genetically engineered cell membranes [197,230]to mimic host cells through the critical surface receptors for viral binding. Zhang et al. synthesized PLGA NPs covered by either cell membrane of epitheliums or macrophages. These NPs are agnostic to current and upcoming coronaviruses since they are immune to various virus species and mutations [199].In adifferent work, the genetically modified membranes were created by transiently transfecting human embryonic kidney (HEK)-293 T-hACE2 cells, after which cell membrane-based NPs were created via sonication and extrusion [197].Rao et al. also made nano-decoys by fusing the cellular membrane of macrophages and HEK-293 T cells with a high level of hACE2. Moreover, many cytokine receptors were present on the fabricated NPs, which can efficiently bind and neutralize inflammatory cytokines like interleukin 6 and granulocyte macrophage colony-stimulating factor, as well as considerably reduce immunological dysfunction and lung damage in a mouse model of acute pneumonia [230]. 3 Challenges and future perspectives of nanotechnology Viral pandemics have introduced a global challenge to the scientific community in the past two centuries. However, many scientists believe that nanotechnology has the potential to overcome these pandemics; there are still several important challenges in high energy consumption, environmental safety, and human health that should be improved. Nanomaterial fabrication requires a lot of water and energy, and the chemicals used are often highly toxic to the environment and human health. Different factors, including the presence, concentration, and pH of organic or inorganic materials, which led to the long-term persistence of NPs in the environment, are well known as environmental pollutants [231]. Some physiochemical properties of the NPs cannotbeprotectedbytheimmuneandinflammatory systemsandleadtoimmunotoxicity,inflammation, and oxidative stress, followed by severe cellular genotoxicity and fibrosis [45]. Therefore, the primary task is promoting the concept of safety by design and then performing the biocompatibility and biodegradability approaches using preclinical (in vitro and in vivo)and clinical studies for a candidate therapeutic, vaccine, medical device, or diagnostic assay [232]. Moreover, these viral pandemics require collective thought beyond ethnic frontiers and cultural diversity. To overcome such complicated challenges and achieve new and critical scientific solutions, a close collaboration among diverse researchers around the world with complementary skills is required [20]. According to this perspective, nanotechnology is an emerging technology where scientists from incredibly various backgrounds have collaborated successfully for improving complex issues in the diagnosis, detection, and treatment of viral diseases [233].The“One Health” concept should be addressed in the future due to the interconnected health of humans, animals, and the environment. 4 Conclusions Retroviruses have shown the potential for pandemic spread worldwide by their high contagious infections, which may lead to unexpected and very serious consequences. Although the current SARS-CoV-2 pandemic highly concerns, it is not among the most extreme threats encountered by humanity because science, technology, and innovation have enabled us to identify, control, and mitigate it. In fact, community hygiene and sanitation practices, effective vaccination, and treatment can shorten the duration of a pandemic. This work discussed nanotechnology’s potential as a platform for preventing, diagnosing, and treating COVID-19 and any future pandemics. There are different types of NPs proposed as promising foundations for counteracting the current global public health threat. These nanosystems are categorized into inorganic NPs (metal/metal oxides, silica)and organic NPs (lipid, protein, polymer, and carbon based)can be intrinsically or extrinsically immunogenic. Finally, the idea of “nanotechnology”can assist scientists in designing NPs for immune regulation in vaccine development and therapy, in the creation of quick, easy, and affordable assays for the diagnosis of COVID-19 and environmental sanitization. Funding information: This work was supported by the Ministry of Education, Youth and Sports of the Czech Republic –DKRVO (RP/CPS/2022/005). Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission. Conflict of interest: The authors state no conflict of interest. References [1]Piret J, Boivin G. Pandemics throughout history. Front Microbiol. 2021;11:3594. SARS-COV-2 and nanotechnology 17 [2]Luby SP. The pandemic potential of Nipah virus. Antivir Res. 2013;100(1):38–43. [3]Doms RW, Moore JP. HIV-1 membrane fusion: Targets of opportunity. J Cell Biol. 2000;151(2):F9–F14. [4]Illanes-Álvarez F, Márquez-Ruiz D, Márquez-Coello M, Cuesta-Sancho S, Girón-González JA. Similarities and differences between HIV and SARS-CoV-2. Int J Med Sci. 2021;18(3):846. [5]Piai A, Fu Q, Sharp AK, Bighi B, Brown AM, Chou JJ. NMR Model of the Entire Membrane-Interacting Region of the HIV-1 Fusion Protein and Its Perturbation of Membrane Morphology. J Am Chem Soc. 2021;143(17):6609–15. [6]Boily M-C, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: Systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009;9(2):118–29. [7]Baggaley RF, Boily M-C, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: A systematic review and meta-analysis. Aids. 2006;20(6):805–12. [8]Amin O, Powers J, Bricker KM, Chahroudi A. Understanding viral and immune interplay during vertical transmission of HIV: Implications for cure. Front Immunol. 2021;12:757400. [9]Chen Z, Julg B. Therapeutic vaccines for the treatment of HIV. Transl Res. 2020;223:61–75. [10]Bailon L, Mothe B, Berman L, Brander C. Novel approaches towards a functional cure of HIV/AIDS. Drugs. 2020;80(9):859–68. [11]Mothe B, Rosás-Umbert M, Coll P, Manzardo C, Puertas MC, Morón-López S, et al. HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: Safety, immunogenicity and effect on the viral reservoir (Study BCN02). Front immunol. 2020;11:823. [12]Webster RG, Monto AS, Braciale TJ, Lamb RA. Textbook of influenza. Germany: Wiley; 2014. [13]Dadonaite B, Gilbertson B, Knight ML, Trifkovic S, Rockman S, Laederach A, et al. The structure of the influenza A virus genome. Nat Microbiol. 2019;4(11):1781–9. [14]Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in human beings. Lancet Infect Dis. 2007;7(4):257–65. [15]Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160(21):3243–7. [16]Sivanandy P, Xien FZ, Kit LW, Wei YT, En KH, Lynn LC. A review on current trends in the treatment of human infection with H7N9-avian influenza A. J Infect public health. 2019;12(2):153–8. [17]Marty AM, Jones MK. The novel coronavirus (SARS-CoV-2)is a one health issue. One Health. 2020;9:100123. [18]Velavan TP, Meyer CG. The COVID‐19 epidemic. Trop Med Int Health. 2020;25(3):278. [19]Wille M, Holmes EC. Wild birds as reservoirs for diverse and abundant gamma-and deltacoronaviruses. FEMS Microbiol Rev. 2020;44(5):631–44. [20]Weiss C, Carriere M, Fusco L, Capua I, Regla-Nava JA, Pasquali M, et al. Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano. 2020;14(6):6383–406. [21]Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22(12):757–73. [22]Izumi H, Nafie LA, Dukor RK. Conformational variability correlation prediction of transmissibility and neutralization escape ability for multiple mutation SARS-CoV-2 strains using SSSCPreds. ACS Omega. 2021;6(29):19323–9. [23]Zhao S, Ran J, Han L. Exploring the interaction between E484K and N501Y substitutions of SARS-CoV-2 in shaping the transmission advantage of COVID-19 in Brazil: A Modeling Study. Am J Trop Med Hyg. 2021;105(5):1247. [24]Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438–43. [25]Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England. Nature. 2021;593(7858):266–9. [26]Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased mortality in community-tested cases of SARS-CoV-2 lineage B. 1.1. 7. Nature. 2021;593(7858):270–4. [27]Hart WS, Miller E, Andrews NJ, Waight P, Maini PK, Funk S, et al. Generation time of the alpha and delta SARS-CoV-2 variants: An epidemiological analysis. Lancet Infect Dis. 2022;22(5):603–10. [28]Dhar MS, Marwal R, Vs R, Ponnusamy K, Jolly B, Bhoyar RC, et al. Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science. 2021;374(6570):995–9. [29]McCallum M, Walls AC, Sprouse KR, Bowen JE, Rosen LE, Dang HV, et al. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science. 2021;374(6575):1621–6. [30]Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DD, Mishra S, et al. Genomics and epidemiology of the P. 1 SARS- CoV-2 lineage in Manaus, Brazil. Science. 2021;372(6544):815–21. [31]Duerr R, Dimartino D, Marier C, Zappile P, Wang G, Lighter J, et al. Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. J Clin Investigation. 2021;131(18):1. [32]Alizon S, Haim-Boukobza S, Foulongne V, Verdurme L, Trombert-Paolantoni S, Lecorche E, et al. Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021. Eurosurveillance. 2021;26(28):2100573. [33]Acevedo ML, Alonso-Palomares L, Bustamante A, Gaggero A, Paredes F, Cortés CP, et al. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. MedRxiv. 2021. [34]Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England. Science. 2021;372(6538):eabg3055. [35]Xie X, Han J-B, Ma G, Feng X-L, Li X, Zou Q-C, et al. Emerging SARS-CoV-2 B. 1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies. Zool Res. 2021;42(6):789. [36]Ghosh N, Nandi S, Saha I. A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein. Int Immunopharmacol. 2022;105:108565. 18 Marjan Motiei et al. [37]Langone M, Petta L, Cellamare C, Ferraris M, Guzzinati R, Mattioli D, et al. SARS-CoV-2 in water services: Presence and impacts. Environ Pollut. 2021;268:115806. [38]Asadi S, Bouvier N, Wexler AS, Ristenpart WD. The coronavirus pandemic and aerosols: Does COVID-19 transmit via expiratory particles?. Aerosol Sci Technol; 2020;54(6):635–8. [39]Yépiz-Gómez MS, Gerba CP, Bright KR. Survival of respiratory viruses on fresh produce. Food Environ Virol. 2013;5(3):150–6. [40]McKinney KR, Gong YY, Lewis TG. Environmental transmission of SARS at Amoy Gardens. J Environ Health. 2006;68(9):26. [41]Amirian ES. Potential fecal transmission of SARS-CoV-2: Current evidence and implications for public health. Int J Infect Dis. 2020;95:363–70. [42]Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831–3.e3. [43]Du L, Yang Y, Zhang X, Li F. Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Nanoscale. 2022;14(4):1054–74. [44]Palestino G, García-Silva I, González-Ortega O, Rosales- Mendoza S. Can nanotechnology help in the fight against COVID-19? Expert Rev Anti-Infect Ther. 2020;18(9):849–64. [45]Rai M, Bonde S, Yadav A, Bhowmik A, Rathod S, Ingle P, et al. Nanotechnology as a shield against COVID-19: Current advancement and limitations. Viruses. 2021;13(7):1224. [46]Motiei M, Aboutalebi F, Forouzanfar M, Dormiani K, Nasr- Esfahani MH, Mirahmadi-Zare SZ. Smart co-delivery of miR- 34a and cytotoxic peptides (LTX-315 and melittin)by chitosan based polyelectrolyte nanocarriers for specific cancer cell death induction. Mater Sci Eng C. 2021;128:112258. [47]Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: The epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti-Infect Ther. 2021;19(7):877–88. [48]Mao L, Chen Z, Wang Y, Chen C. Design and application of nanoparticles as vaccine adjuvants against human corona virus infection. J Inorg Biochem. 2021;219:111454. [49]Duan Y, Wang S, Zhang Q, Gao W, Zhang L. Nanoparticle approaches against SARS-CoV-2 infection. Curr OpSolid State Mater Sci. 2021;25(6):100964. [50]Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunology. 2018;9:2224. [51]Zhang N, Li C, Jiang S, Du L. Recent advances in the development of virus-like particle-based flavivirus vaccines. Vaccines. 2020;8(3):481. [52]Zhang N-N, Li X-F, Deng Y-Q, Zhao H, Huang Y-J, Yang G, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271–83.e16. [53]Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. A single immunization with nucleosidemodified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53(4):724–32.e7. [54]Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. [55]Walsh EE, Frenck Jr RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA- based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50. [56]Kaiser RA, Haller MC, Apfalter P, Kerschner H, Cejka D. Comparison of BNT162b2 (Pfizer–BioNtech)and mRNA-1273 (Moderna)SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients. Kidney Int. 2021;100(3):697–8. [57]Huang WC, Zhou S, He X, Chiem K, Mabrouk MT, Nissly RH, et al. SARS‐CoV‐2 RBD neutralizing antibody induction is enhanced by particulate vaccination. Adv Mater. 2020;32(50):2005637. [58]Peng S, Cao F, Xia Y, Gao XD, Dai L, Yan J, et al. Particulate alum via pickering emulsion for an enhanced COVID‐19 vaccine adjuvant. Adv Mater. 2020;32(40):2004210. [59]Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;11:298. [60]Kanekiyo M, Wei C-J, Yassine HM, McTamney PM, Boyington JC, Whittle JR, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013;499(7456):102–6. [61]Tokatlian T, Read BJ, Jones CA, Kulp DW, Menis S, Chang JY, et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science. 2019;363(6427):649–54. [62]Tan TK, Rijal P, Rahikainen R, Keeble AH, Schimanski L, Hussain S, et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat Commun. 2021;12(1):1–16. [63]Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell. 2020;183(5):1367–82.e17. [64]Powell AE, Zhang K, Sanyal M, Tang S, Weidenbacher PA, Li S, et al. A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. ACS Cent Sci. 2021;7(1):183–99. [65]Wang W, Huang B, Zhu Y, Tan W, Zhu M. Ferritin nanoparticlebased SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice. Cell Mol Immunol. 2021;18(3):749–51. [66]Saunders KO, Lee E, Parks R, Martinez DR, Li D, Chen H, et al. Neutralizing antibody vaccine for pandemic and pre-emer- gent coronaviruses. Nature. 2021;594(7864):553–9. [67]Ma X, Zou F, Yu F, Li R, Yuan Y, Zhang Y, et al. Nanoparticle vaccines based on the receptor binding domain (RBD)and heptad repeat (HR)of SARS-CoV-2 elicit robust protective immune responses. Immunity. 2020;53(6):1315–30.e9. [68]Huang X, Kon E, Han X, Zhang X, Kong N, Mitchell MJ, et al. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat Nanotechnol. 2022;17(10):1027–37. [69]Kumar N, Admane N, Kumari A, Sood D, Grover S, Prajapati VK, et al. Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework. Sci Rep. 2021;11(1):1–14. [70]Sahoo B, Kant K, Rai NK, Chaudhary DK. Identification of T-cell epitopes in proteins of novel human coronavirus, SARS-Cov-2 for vaccine development. Int J Appl Biol Pharm Technol. 2020;11(2):37–45. SARS-COV-2 and nanotechnology 19 [71]Chan Y, Ng SW, Singh SK, Gulati M, Gupta G, Chaudhary SK, et al. Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective. Life Sci. 2021;280:119744. [72]Mohamed SH, Arafa AS, Mady WH, Fahmy HA, Omer LM, Morsi RE. Preparation and immunological evaluation of inactivated avian influenza virus vaccine encapsulated in chitosan nanoparticles. Biologicals. 2018;51:46–53. [73]Huang T, Song X, Jing J, Zhao K, Shen Y, Zhang X, et al. Chitosan-DNA nanoparticles enhanced the immunogenicity of multivalent DNA vaccination on mice against Trueperella pyogenes infection. J Nanobiotechnol. 2018;16(1):1–15. [74]Verheul RJ, Slütter B, Bal SM, Bouwstra JA, Jiskoot W, Hennink WE. Covalently stabilized trimethyl chitosan-hya- luronic acid nanoparticles for nasal and intradermal vaccination. J Controlled Release. 2011;156(1):46–52. [75]Yu H, Lin H, Xie Y, Qu M, Jiang M, Shi J, et al. MUC1 vaccines using β-cyclodextrin grafted chitosan (CS–g–CD)as carrier via host-guest interaction elicit robust immune responses. Chin Chem Lett. 2022;33(11):4882–5. [76]Rocha CE, Silva MF, Guedes AC, Carvalho TP, Eckstein C, Ribeiro NQ, et al. Alginate-chitosan microcapsules improve vaccine potential of gamma-irradiated Listeria monocytogenes against listeriosis in murine model. Int J Biol Macromolecules. 2021;176:567–77. [77]Stiepel RT, Batty CJ, MacRaild CA, Norton RS, Bachelder E, Ainslie KM. Merozoite surface protein 2 adsorbed onto acetalated dextran microparticles for malaria vaccination. Int J Pharmaceutics. 2021;593:120168. [78]Nakahashi-Ouchida R, Yuki Y, Kiyono H. Cationic pullulan nanogel as a safe and effective nasal vaccine delivery system for respiratory infectious diseases. Hum Vaccines Immunother. 2018;14(9):2189–93. [79]Ferrell KC, Stewart EL, Counoupas C, Ashhurst TM, Britton WJ, Petrovsky N, et al. Intrapulmonary vaccination with deltainulin adjuvant stimulates non-polarised chemotactic signalling and diverse cellular interaction. Mucosal Immunol. 2021;14(3):762–73. [80]Bandeira AC, de Oliveira Matos A, Evangelista BS, da Silva SM, Nagib PRA, de Moraes Crespo A, et al. Is it possible to track intracellular chitosan nanoparticles using magnetic nanoparticles as contrast agent? Bioorg Med Chem. 2019;27(12):2637–43. [81]Hiremath J, Kang K-I, Xia M, Elaish M, Binjawadagi B, Ouyang K, et al. Entrapment of H1N1 influenza virus derived conserved peptides in PLGA nanoparticles enhances T cell response and vaccine efficacy in pigs. PLoS One. 2016;11(4):e0151922. [82]Singh J, Pandit S, Bramwell VW, Alpar HO. Diphtheria toxoid loaded poly-(ε-caprolactone)nanoparticles as mucosal vaccine delivery systems. Methods. 2006;38(2):96–105. [83]Zhang D, Atochina-Vasserman EN, Maurya DS, Liu M, Xiao Q, Lu J, et al. Targeted delivery of mRNA with one-component ionizable amphiphilic janus dendrimers. J Am Chem Soc. 2021;143(43):17975–82. [84]Ren S, Guo L, Wang C, Ru J, Yang Y, Wang Y, et al. Construction of an effective delivery system for DNA vaccines using biodegradable polylactic acid based microspheres. J Biomed Nanotechnol. 2021;17(5):971–80. [85]Stephens LM, Ross KA, Waldstein KA, Legge KL, McLellan JS, Narasimhan B, et al. Prefusion F–based polyanhydride nanovaccine induces both humoral and cell-mediated immunity resulting in long-lasting protection against respiratory syncytial virus. J Immunol. 2021;206(9):2122–34. [86]Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of the mRNA‐1273 vaccine for COVID‐19: Possible involvement of polyethylene glycol and IgG‐mediated complement activation. Allergy. 2021;76(11):3307–13. [87]Guo S, Fu D, Utupova A, Sun D, Zhou M, Jin Z, et al. Applications of polymer-based nanoparticles in vaccine field. Nanotechnol Rev. 2019;8(1):143–55. [88]Hess KL, Medintz IL, Jewell CM. Designing inorganic nanomaterials for vaccines and immunotherapies. Nano Today. 2019;27:73–98. [89]Zhou Q, Zhang Y, Du J, Li Y, Zhou Y, Fu Q, et al. Different-sized gold nanoparticle activator/antigen increases dendritic cells accumulation in liver-draining lymph nodes and CD8 +T cell responses. ACS Nano. 2016;10(2):2678–92. [90]Hu Z, Song B, Xu L, Zhong Y, Peng F, Ji X, et al. Aqueous synthesized quantum dots interfere with the NF-κB pathway and confer anti-tumor, anti-viral and anti-inflammatory effects. Biomaterials. 2016;108:187–96. [91]Versiani AF, Astigarraga RG, Rocha ES, Barboza APM, Kroon EG, Rachid MA, et al. Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice. J Nanobiotechnol. 2017;15(1):1–13. [92]Pescatori M, Bedognetti D, Venturelli E, Ménard-Moyon C, Bernardini C, Muresu E, et al. Functionalized carbon nanotubes as immunomodulator systems. Biomaterials. 2013;34(18):4395–403. [93]Qiao L, Chen M, Li S, Hu J, Gong C, Zhang Z, et al. A peptidebased subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice. Biomater Sci. 2021;9(21):7287–96. [94]Motamedi‐sedeh F, Saboorizadeh A, Khalili I, Sharbatdaran M, Wijewardana V, Arbabi A. Carboxymethyl chitosan bounded iron oxide nanoparticles and gammairradiated avian influenza subtype H9N2 vaccine to development of immunity on mouse and chicken. Vet Med Sci. 2021;8(2):626–34. [95]Orecchioni M, Bedognetti D, Newman L, Fuoco C, Spada F, Hendrickx W, et al. Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells. Nat Commun. 2017;8(1):1–14. [96]Xu L, Xiang J, Liu Y, Xu J, Luo Y, Feng L, et al. Functionalized graphene oxide serves as a novel vaccine nano-adjuvant for robust stimulation of cellular immunity. Nanoscale. 2016;8(6):3785–95. [97]Bilyy R, Pagneux Q, François N, Bila G, Grytsko R, Lebedin Y, et al. Rapid generation of coronaviral immunity using recombinant peptide modified nanodiamonds. Pathogens. 2021;10(7):861. [98]Cao W, He L, Cao W, Huang X, Jia K, Dai J. Recent progress of graphene oxide as a potential vaccine carrier and adjuvant. Acta biomaterialia. 2020;112:14–28. 20 Marjan Motiei et al. [99]Bakkar MR, Faraag AHI, Soliman ER, Fouda MS, Sarguos AMM, McLean GR, et al. Rhamnolipids nanomicelles as a potential hand sanitizer. Antibiotics. 2021;10(7):751. [100]Monge FA, Jagadesan P, Bondu V, Donabedian PL, Ista L, Chi EY, et al. Highly effective inactivation of SARS-CoV-2by conjugated polymers and oligomers. ACS Appl Mater Interfaces. 2020;12(50):55688–95. [101]Chowdhury MA, Shuvho MBA, Shahid MA, Haque AM, Kashem MA, Lam SS, et al. Prospect of biobased antiviral face mask to limit the coronavirus outbreak. Environ Res. 2021;192:110294. [102]Zhong H, Zhu Z, Lin J, Cheung CF, Lu VL, Yan F, et al. Reusable and recyclable graphene masks with outstanding superhydrophobic and photothermal performances. ACS nano. 2020;14(5):6213–21. [103]Kasbe PS, Gade H, Liu S, Chase GG, Xu W. Ultrathin polydopamine-graphene oxide hybrid coatings on polymer filters with improved filtration performance and functionalities. ACS Appl Bio Mater. 2021;4(6):5180–8. [104]Gopal V, Nilsson-Payant BE, French H, Siegers JY, Yung W-S, Hardwick M, et al. Zinc-embedded polyamide fabrics inactivate SARS-CoV-2 and influenza a virus. ACS Appl Mater Interfaces. 2021;13(26):30317–25. [105]Jung S, Yang J-Y, Byeon E-Y, Kim D-G, Lee D-G, Ryoo S, et al. Copper-coated polypropylene filter face mask with SARSCOV-2 antiviral ability. Polymers. 2021;13(9):1367. [106]Joe YH, Park DH, Hwang J. Evaluation of Ag nanoparticle coated air filter against aerosolized virus: Anti-viral efficiency with dust loading. J Hazard Mater. 2016;301:547–53. [107]Kumar A, Sharma A, Chen Y, Jones MM, Vanyo ST, Li C, et al. Copper@ ZIF‐8 core‐shell nanowires for reusable antimicrobial face masks. Adv Funct Mater. 2021;31(10):2008054. [108]Balagna C, Perero S, Percivalle E, Nepita EV, Ferraris M. Virucidal effect against coronavirus SARS-CoV-2 of a silver nanocluster/silica composite sputtered coating. Open Ceram. 2020;1:100006. [109]Abbas WA, Shaheen BS, Ghanem LG, Badawy IM, Abodouh MM, Abdou SM, et al. Cost-effective face mask filter based on hybrid composite nanofibrous layers with high filtration efficiency. Langmuir. 2021;37(24):7492–502. [110]Kumar S, Karmacharya M, Joshi SR, Gulenko O, Park J, Kim G- H, et al. Photoactive antiviral face mask with self-sterilization and reusability. Nano Lett. 2020;21(1):337–43. [111]He R, Li J, Chen M, Zhang S, Cheng Y, Ning X, et al. Tailoring moisture electroactive Ag/Zn@ cotton coupled with electrospun PVDF/PS nanofibers for antimicrobial face masks. J Hazard Mater. 2022;428:128239. [112]Ciejka J, Wolski K, Nowakowska M, Pyrc K, Szczubiałka K. Biopolymeric nano/microspheres for selective and reversible adsorption of coronaviruses. Mater Sci Eng C. 2017;76:735–42. [113]Gupta I, Chakraborty J, Roy S, Farinas ET, Mitra S. Nanocarbon immobilized membranes for generating bacteria and endotoxin free water via membrane distillation. Sep Purif Technol. 2021;259:118133. [114]Zheng X, Shen Z-P, Cheng C, Shi L, Cheng R, Yuan D-H. Photocatalytic disinfection performance in virus and virus/ bacteria system by Cu-TiO 2 nanofibers under visible light. Environ Pollut. 2018;237:452–9. [115]Kusiak-Nejman E, Morawski AW. TiO 2 /graphene-based nanocomposites for water treatment: A brief overview of charge carrier transfer, antimicrobial and photocatalytic performance. Appl Catal B Environ. 2019;253:179–86. [116]Liu H, Huang J, Mao J, Chen Z, Chen G, Lai Y. Transparent antibacterial nanofiber air filters with highly efficient moisture resistance for sustainable particulate matter capture. Iscience. 2019;19:214–23. [117]Stanford MG, Li JT, Chen Y, McHugh EA, Liopo A, Xiao H, et al. Self-sterilizing laser-induced graphene bacterial air filter. ACS nano. 2019;13(10):11912–20. [118]Sun W-H, Hui L-F, Yang Q, Zhao G-D. Nanofiltration filter paper based on multi-walled carbon nanotubes and cellulose filter papers. RSC Adv. 2021;11(2):1194–9. [119]Deshmukh SP, Patil S, Mullani S, Delekar S. Silver nanoparticles as an effective disinfectant: A review. Mater Sci Eng C. 2019;97:954–65. [120]Ko Y-S, Joe YH, Seo M, Lim K, Hwang J, Woo K. Prompt and synergistic antibacterial activity of silver nanoparticle-deco- rated silica hybrid particles on air filtration. J Mater Chem B. 2014;2(39):6714–22. [121]Han J, Chen L, Duan S-M, Yang Q-X, Yang M, Gao C, et al. Efficient and quick inactivation of SARS coronavirus and other microbes exposed to the surfaces of some metal catalysts. Biomed Environ Sci BES. 2005;18(3):176–80. [122]Wang I-J, Chen Y-C, Su C, Tsai M-H, Shen W-T, Bai C-H, et al. Effectiveness of the Nanosilver/TiO 2 -chitosan antiviral filter on the removal of viral aerosols. J Aerosol Med Pulm Drug Delivery. 2021;34(5):293–302. [123]Heo KJ, Jeong SB, Shin J, Hwang GB, Ko HS, Kim Y, et al. Water-repellent TiO 2 -organic dye-based air filters for efficient visible-light-activated photochemical inactivation against bioaerosols. Nano Lett. 2020;21(4):1576–83. [124]Lv D, Wang R, Tang G, Mou Z, Lei J, Han J, et al. Ecofriendly electrospun membranes loaded with visible-light- responding nanoparticles for multifunctional usages: Highly efficient air filtration, dye scavenging, and bactericidal activity. ACS Appl Mater Interfaces. 2019;11(13):12880–9. [125]Milewska A, Chi Y, Szczepanski A, Barreto-Duran E, Liu K, Liu D, et al. HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV. BioRxiv. 2020. [126]Khaiboullina S, Uppal T, Dhabarde N, Subramanian VR, Verma SC. Inactivation of human coronavirus by titania nanoparticle coatings and UVC radiation: Throwing light on SARS-CoV-2. Viruses. 2020;13(1):19. [127]Jeremiah SS, Miyakawa K, Morita T, Yamaoka Y, Ryo A. Potent antiviral effect of silver nanoparticles on SARS-CoV-2. Biochemical biophysical Res Commun. 2020;533(1):195–200. [128]Zhu P, Wang Y, Chu H, Wang L. Superhydrophobicity preventing surface contamination as a novel strategy against COVID-19. J Colloid Interface Sci. 2021;600:613–9. [129]Hamouda T, Ibrahim HM, Kafafy H, Mashaly H, Mohamed NH, Aly NM. Preparation of cellulose-based wipes treated with antimicrobial and antiviral silver nanoparticles as novel effective high-performance coronavirus fighter. Int J Biol macromolecules. 2021;181:990–1002. [130]Behzadinasab S, Chin A, Hosseini M, Poon L, Ducker WA. A surface coating that rapidly inactivates SARS-CoV-2. ACS Appl Mater Interfaces. 2020;12(31):34723–7. SARS-COV-2 and nanotechnology 21 [131]Asadi S, Bouvier N, Wexler AS, Ristenpart WD. The coronavirus pandemic and aerosols: Does COVID-19 transmit via expiratory particles?. Aerosol Sci Technol; 2020;54(6):635–8. [132]Mallakpour S, Azadi E, Hussain CM. Fabrication of air filters with advanced filtration performance for removal of viral aerosols and control the spread of COVID-19. Adv Colloid Interface Sci. 2022;303:102653. [133]Alghoraibi I, Alomari S. Different methods for nanofiber design and fabrication. Handbook of Nanofibers; 2018. p. 1–46. [134]Bhattacharjee S, Joshi R, Yasir M, Adhikari A, Chughtai AA, Heslop D, et al. Graphene-and Nanoparticle-Embedded Antimicrobial and Biocompatible Cotton/Silk Fabrics for Protective Clothing. ACS Appl Bio Mater. 2021;4(8):6175–85. [135]Jeong SB, Lee DU, Lee BJ, Heo KJ, Kim DW, Hwang GB, et al. Photobiocidal-triboelectric nanolayer coating of photosensitizer/silica–alumina for reusable and visible-light-driven antibacterial/antiviral air filters. Chem Eng J. 2022;440:135830. [136]Borkow G, Zhou SS, Page T, Gabbay J. A novel anti-influenza copper oxide containing respiratory face mask. PLoS One. 2010;5(6):e11295. [137]Karagoz S, Kiremitler NB, Sarp G, Pekdemir S, Salem S, Goksu AG, et al. Antibacterial, antiviral, and self-cleaning mats with sensing capabilities based on electrospun nanofibers decorated with ZnO nanorods and Ag nanoparticles for protective clothing applications. ACS Appl Mater Interfaces. 2021;13(4):5678–90. [138]Lee B-Y, Behler K, Kurtoglu ME, Wynosky-DolfiMA, Rest RF, Gogotsi Y. Titanium dioxide-coated nanofibers for advanced filters. J Nanopart Res. 2010;12(7):2511–9. [139]Ramaiah GB, Tegegne A, Melese B. Developments in nanomaterials and analysing its role in fighting COVID-19. Mater Today Proc. 2021;47:4357–63. [140]Phuna ZX, Panda BP, Hawala Shivashekaregowda NK, Madhavan P. Nanoprotection from SARS-COV-2: Would nanotechnology help in Personal Protection Equipment (PPE) to control the transmission of COVID-19? Int J Environ Health Res. 2022;1–30. [141]Fibriana F, Amalia AV, Muntamah S, Ulva L, Aryanti S. Antimicrobial activities of green synthesized silver nanoparticles from Marchantia sp. extract: Testing an alcohol-free hand sanitizer product formula. J microbiol Biotechnol Food Sci. 2020;9(6):1034–8. [142]Malabadi RB, Kolkar KP, Meti NT, Chalannavar RK. Role of plant based hand sanitizers during the recent outbreak of coronavirus (SARS-CoV-2)disease (Covid-19). Significances Bioeng Biosci. 2021;5(1):458–68. [143]Tran HN, Le GT, Nguyen DT, Juang R-S, Rinklebe J, Bhatnagar A, et al. SARS-CoV-2 coronavirus in water and wastewater: A critical review about presence and concern. Environ Res. 2021;193:110265. [144]Romano-Bertrand S, Glele LA, Grandbastien B, Lepelletier D. Preventing SARS-CoV-2 transmission in rehabilitation pools and therapeutic water environments. J Hosp Infect. 2020;105(4):625–7. [145]Rimoldi SG, Stefani F, Gigantiello A, Polesello S, Comandatore F, Mileto D, et al. Presence and infectivity of SARS-CoV-2 virus in wastewaters and rivers. Sci Total Environ. 2020;744:140911. [146]Nasir AM, Adam MR, Kamal SNEAM, Jaafar J, Othman MHD, Ismail AF, et al. A review of the potential of conventional and advanced membrane technology in the removal of pathogens from wastewater. Sep Purif Technol. 2022;286:120454. [147]Hardikar M, Ikner LA, Felix V, Presson LK, Rabe AB, Hickenbottom KL, et al. Membrane distillation provides a dual barrier for coronavirus and bacteriophage removal. Environ Sci Technol Lett. 2021;8(8):713–8. [148]Nthunya LN, Gutierrez L, Khumalo N, Derese S, Mamba BB, Verliefde AR, et al. Superhydrophobic PVDF nanofibre membranes coated with an organic fouling resistant hydrophilic active layer for direct-contact membrane distillation. Colloids Surf A. 2019;575:363–72. [149]Biryukov J, Boydston JA, Dunning RA, Yeager JJ, Wood S, Ferris A, et al. SARS-CoV-2 is rapidly inactivated at high temperature. Environ Chem Lett. 2021;19(2):1773–7. [150]Soni V, Khosla A, Singh P, Nguyen V-H, Van Le Q, Selvasembian R, et al. Current perspective in metal oxide based photocatalysts for virus disinfection: A review. J Environ Manag. 2022;308:114617. [151]Liu L, Meng G, Chen H, Wang C, Xue Y. Photocatalytic disinfection of different airborne microorganisms by TiO 2 /MXene filler: Inactivation efficiency, energy consumption and selfrepair phenomenon. J Environ Chem Eng. 2022;10:107641. [152]Nasir AM, Awang N, Hubadillah SK, Jaafar J, Othman MHD, Salleh WNW, et al. A review on the potential of photocatalysis in combatting SARS-CoV-2 in wastewater. J Water Process Eng. 2021;42:102111. [153]Moor KJ, Valle DC, Li C, Kim J-H. Improving the visible light photoactivity of supported fullerene photocatalysts through the use of [C70]fullerene. Environ Sci Technol. 2015;49(10):6190–7. [154]Banerjee I, Douaisi MP, Mondal D, Kane RS. Light-activated nanotube–porphyrin conjugates as effective antiviral agents. Nanotechnology. 2012;23(10):105101. [155]Łoczechin A, Séron K, Barras A, Giovanelli E, Belouzard S, Chen Y-T, et al. Functional carbon quantum dots as medical countermeasures to human coronavirus. ACS Appl Mater Interfaces. 2019;11(46):42964–74. [156]Zhang C, Li Y, Wang C, Zheng X. Different inactivation behaviors and mechanisms of representative pathogens (Escherichia coli bacteria, human adenoviruses and Bacillus subtilis spores)in g-C3N4-based metal-free visible-light- enabled photocatalytic disinfection. Sci Total Environ. 2021;755:142588. [157]Shi Y, Huang J, Zeng G, Cheng W, Hu J. Photocatalytic membrane in water purification: Is it stepping closer to be driven by visible light? J Membr Sci. 2019;584:364–92. [158]Doremalen NV, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–7. [159]Vaze N, Pyrgiotakis G, McDevitt J, Mena L, Melo A, Bedugnis A, et al. Inactivation of common hospital acquired pathogens on surfaces and in air utilizing engineered water nanostructures (EWNS)based nano-sanitizers. Nanomedicine Nanotechnol Biol Med. 2019;18:234–42. [160]Ereth M, Fine J, Stamatatos F, Mathew B, Hess D, Simpser E. Healthcare-associated infection impact with bioaerosol 22 Marjan Motiei et al. treatment and COVID-19 mitigation measures. J Hosp Infect. 2021;116:69–77. [161]Blocken B, van Druenen T, Ricci A, Kang L, van HooffT, Qin P, et al. Ventilation and air cleaning to limit aerosol particle concentrations in a gym during the COVID-19 pandemic. Build Environ. 2021;193:107659. [162]Yoon K-Y, Byeon JH, Park J-H, Ji JH, Bae GN, Hwang J. Antimicrobial characteristics of silver aerosol nanoparticles against Bacillus subtilis bioaerosols. Environ Eng Sci. 2008;25(2):289–94. [163]Fan X, Rong L, Kong L, Li Y, Huang J, Cao Y, et al. Tug-of-war- inspired bio-based air filters with advanced filtration performance. ACS Appl Mater Interfaces. 2021;13(7):8736–44. [164]Patial S, Kumar A, Raizada P, Van Le Q, Selvasembian R, Singh P, et al. Potential of Graphene based photocatalyst for antiviral activity with emphasis on COVID-19: A review. J Environ Chem Eng. 2022;10:107527. [165]Lim ME, Lee Y-L, Zhang Y, Chu JJH. Photodynamic inactivation of viruses using upconversion nanoparticles. Biomaterials. 2012;33(6):1912–20. [166]Kaiser J-P, Zuin S, Wick P. Is nanotechnology revolutionizing the paint and lacquer industry? A critical opinion. Sci Total Environ. 2013;442:282–9. [167]Kumar R, Nayak M, Sahoo GC, Pandey K, Sarkar MC, Ansari Y, et al. Iron oxide nanoparticles based antiviral activity of H1N1 influenza A virus. J Infect Chemother. 2019;25(5):325–9. [168]Lin N, Verma D, Saini N, Arbi R, Munir M, Jovic M, et al. Antiviral nanoparticles for sanitizing surfaces: A roadmap to self-sterilizing against COVID-19. Nano Today. 2021;40:101267. [169]Wiehe A, O’Brien JM, Senge MO. Trends and targets in antiviral phototherapy. Photochem Photobiol Sci. 2019;18(11):2565–612. [170]Ting D, Dong N, Fang L, Lu J, Bi J, Xiao S, et al. Multisite inhibitors for enteric coronavirus: Antiviral cationic carbon dots based on curcumin. ACS Appl Nano Mater. 2018;1(10):5451–9. [171]Milewska A, Kaminski K, Ciejka J, Kosowicz K, Zeglen S, Wojarski J, et al. HTCC: Broad range inhibitor of coronavirus entry. PLoS One. 2016;11(6):e0156552. [172]Smith RJ, Moule MG, Sule P, Smith T, Cirillo JD, Grunlan JC. Polyelectrolyte multilayer nanocoating dramatically reduces bacterial adhesion to polyester fabric. ACS Biomater Sci Eng. 2017;3(8):1845–52. [173]Ventura BD, Cennamo M, Minopoli A, Campanile R, Censi SB, Terracciano D, et al. Colorimetric test for fast detection of SARS-CoV-2 in nasal and throat swabs. ACS Sens. 2020;5(10):3043–8. [174]Hassanzadeh P. Nanotheranostics against COVID-19: From multivalent to immune-targeted materials. J. Controlled Release. 2020;328:112–26. [175]Huang C, Wen T, Shi F-J, Zeng X-Y, Jiao Y-J. Rapid detection of IgM antibodies against the SARS-CoV-2 virus via colloidal gold nanoparticle-based lateral-flow assay. ACS Omega. 2020;5(21):12550–6. [176]Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis. J Med Virol. 2020;92(9):1518–24. [177]Baker AN, Richards S-J, Guy CS, Congdon TR, Hasan M, Zwetsloot AJ, et al. The SARS-COV-2 spike protein binds sialic acids and enables rapid detection in a lateral flow point of care diagnostic device. ACS Cent Sci. 2020;6(11):2046–52. [178]Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D. Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS nano. 2020;14(6):7617–27. [179]Liu H, Dai E, Xiao R, Zhou Z, Zhang M, Bai Z, et al. Development of a SERS-based lateral flow immunoassay for rapid and ultra-sensitive detection of anti-SARS-CoV-2 IgM/ IgG in clinical samples. Sens Actuators B. 2021;329:129196. [180]Chen Z, Zhang Z, Zhai X, Li Y, Lin L, Zhao H, et al. Rapid and sensitive detection of anti-SARS-CoV-2 IgG, using lanthanide-doped nanoparticles-based lateral flow immunoassay. Anal Chem. 2020;92(10):7226–31. [181]Wang Z, Zheng Z, Hu H, Zhou Q, Liu W, Li X, et al. A point-of- care selenium nanoparticle-based test for the combined detection of anti-SARS-CoV-2 IgM and IgG in human serum and blood. Lab-on-a-Chip. 2020;20(22):4255–61. [182]Wang D, He S, Wang X, Yan Y, Liu J, Wu S, et al. Rapid lateral flow immunoassay for the fluorescence detection of SARS- CoV-2 RNA. Nat Biomed Eng. 2020;4(12):1150–8. [183]Seo G, Lee G, Kim MJ, Baek S-H, Choi M, Ku KB, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2)in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS nano. 2020;14(4):5135–42. [184]Khoris IM, Ganganboina AB, Suzuki T, Park EY. Selfassembled chromogen-loaded polymeric cocoon for respiratory virus detection. Nanoscale. 2021;13(1):388–96. [185]Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis—A review of current methods. Biosens Bioelectron. 2021;172:112752. [186]Kyle S. Affimer proteins: Theranostics of the future? Trends Biochem Sci. 2018;43(4):230–2. [187]Singh R, Hong S, Jang J. Label-free detection of influenza viruses using a reduced graphene oxide-based electrochemical immunosensor integrated with a microfluidic platform. Sci Rep. 2017;7(1):1–11. [188]Qomara WF, Primanissa DN, Amalia SH, Purwadi FV, Zakiyah N. Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: A systematic review. Int J Gen Med. 2021;14:8557. [189]Fabra MJ, Falcó I, Randazzo W, Sánchez G, López-Rubio A. Antiviral and antioxidant properties of active alginate edible films containing phenolic extracts. Food Hydrocoll. 2018;81:96–103. [190]Soria-Martinez L, Bauer S, Giesler M, Schelhaas S, Materlik J, Janus K, et al. Prophylactic antiviral activity of sulfated glycomimetic oligomers and polymers. J Am Chem Soc. 2020;142(11):5252–65. [191]Günther SC, Maier JD, Vetter J, Podvalnyy N, Khanzhin N, Hennet T, et al. Antiviral potential of 3′-sialyllactose-and 6′- sialyllactose-conjugated dendritic polymers against human and avian influenza viruses. Sci Rep. 2020;10(1):1–9. [192]Donskyi IS, Nie C, Ludwig K, Trimpert J, Ahmed R, Quaas E, et al. Graphene sheets with defined dual functionalities for the strong SARS‐CoV‐2 interactions. Small. 2021;17(11):2007091. SARS-COV-2 and nanotechnology 23 [193]Ramos-Soriano J, Reina JJ, Illescas BM, De La Cruz N, Rodriguez-Perez L, Lasala F, et al. Synthesis of highly efficient multivalent disaccharide/[60]fullerene nanoballs for emergent viruses. J Am Chem Soc. 2019;141(38):15403–12. [194]Tong T, Hu H, Zhou J, Deng S, Zhang X, Tang W, et al. Glycyrrhizic‐acid‐based carbon dots with high antiviral activity by multisite inhibition mechanisms. Small. 2020;16(13):1906206. [195]Kim H-E, Lee H-J, Kim MS, Kim T, Lee H, Kim H-H, et al. Differential microbicidal effects of bimetallic iron–copper nanoparticles on Escherichia coli and MS2 Coliphage. Environ Sci Technol. 2019;53(5):2679–87. [196]Kim J, Mukherjee A, Nelson D, Jozic A, Sahay G. Rapid generation of circulating and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2. BioRxiv. 2020. [197]Wang C, Wang S, Chen Y, Zhao J, Han S, Zhao G, et al. Membrane nanoparticles derived from ACE2-rich cells block SARS-CoV-2 infection. ACS nano. 2021;15(4):6340–51. [198]Surnar B, Kamran MZ, Shah AS, Dhar S. Clinically approved antiviral drug in an orally administrable nanoparticle for COVID-19. ACS Pharmacol Transl Sci. 2020;3(6):1371–80. [199]Zhang Q, Honko A, Zhou J, Gong H, Downs SN, Vasquez JH, et al. Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett. 2020;20(7):5570–4. [200]Morad R, Akbari M, Rezaee P, Koochaki A, Maaza M, Jamshidi Z. First principle simulation of coated hydroxychloroquine on Ag, Au and Pt nanoparticles. Sci Rep. 2021;11(1):1–9. [201]Neufurth M, Wang X, Tolba E, Lieberwirth I, Wang S, Schröder HC, et al. The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations. Biochem Pharmacol. 2020;182:114215. [202]Martínez-Abad A, Ocio M, Lagarón J, Sánchez G. Evaluation of silver-infused polylactide films for inactivation of Salmonella and feline calicivirus in vitro and on fresh-cut vegetables. Int J Food Microbiol. 2013;162(1):89–94. [203]Hu R, Li S, Kong F, Hou R, Guan X, Guo F. Inhibition effect of silver nanoparticles on herpes simplex virus 2. Genet Mol Res. 2014;13(3):7022–8. [204]Park HH, Park S, Ko G, Woo K. Magnetic hybrid colloids decorated with Ag nanoparticles bite away bacteria and chemisorb viruses. J Mater Chem B. 2013;1(21):2701–9. [205]Castro Mayorga JL, Fabra Rovira MJ, Cabedo Mas L, Sánchez Moragas G, Lagarón Cabello JM. Antimicrobial nanocomposites and electrospun coatings based on poly (3‐hydroxybu- tyrate‐co‐3‐hydroxyvalerate)and copper oxide nanoparticles for active packaging and coating applications. J Appl Polym Sci. 2018;135(2):45673. [206]Baram‐Pinto D, Shukla S, Gedanken A, Sarid R. Inhibition of HSV‐1 attachment, entry, and cell‐to‐cell spread by functionalized multivalent gold nanoparticles. Small. 2010;6(9):1044–50. [207]Dunnill CW, Parkin IP. Nitrogen-doped TiO 2 thin films: Photocatalytic applications for healthcare environments. Dalton Trans. 2011;40(8):1635–40. [208]Govorov AO, Richardson HH. Generating heat with metal nanoparticles. Nano Today. 2007;2(1):30–8. [209]Bogdan J, Zarzyńska J, Pławińska-Czarnak J. Comparison of infectious agents susceptibility to photocatalytic effects of nanosized titanium and zinc oxides: A practical approach. Nanoscale Res Lett. 2015;10(1):1–15. [210]Serrano-Aroca Á, Takayama K, Tuñón-Molina A, Seyran M, Hassan SS, Pal Choudhury P, et al. Carbon-based nanomaterials: Promising antiviral agents to combat COVID-19 in the microbial-resistant era. ACS nano. 2021;15(5):8069–86. [211]Sametband M, Kalt I, Gedanken A, Sarid R. Herpes simplex virus type-1 attachment inhibition by functionalized graphene oxide. ACS Appl Mater Interfaces. 2014;6(2):1228–35. [212]Ye S, Shao K, Li Z, Guo N, Zuo Y, Li Q, et al. Antiviral activity of graphene oxide: How sharp edged structure and charge matter. ACS Appl Mater Interfaces. 2015;7(38):21571–9. [213]Gholami MF, Lauster D, Ludwig K, Storm J, Ziem B, Severin N, et al. Functionalized graphene as extracellular matrix mimics: Toward well‐defined 2D nanomaterials for multivalent virus interactions. Adv Funct Mater. 2017;27(15):1606477. [214]Vaillant A. Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Antivir Res. 2016;133:32–40. [215]Tengdelius M, Lee C-J, Grenegård M, Griffith M, Påhlsson P, Konradsson P. Synthesis and biological evaluation of fucoidan-mimetic glycopolymers through cyanoxyl-mediated free-radical polymerization. Biomacromolecules. 2014;15(7):2359–68. [216]Longarela OL, Schmidt TT, Schöneweis K, Romeo R, Wedemeyer H, Urban S, et al. Proteoglycans act as cellular hepatitis delta virus attachment receptors. PLoS One. 2013;8(3):e58340. [217]Richards KF, Bienkowska-Haba M, Dasgupta J, Chen XS, Sapp M. Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J Virol. 2013;87(21):11426–37. [218]Cerqueira C, Liu Y, Kühling L, Chai W, Hafezi W, van Kuppevelt TH, et al. Heparin increases the infectivity of Human Papillomavirus Type 16 independent of cell surface proteoglycans and induces L1 epitope exposure. Cell Microbiol. 2013;15(11):1818–36. [219]Dey P, Bergmann T, Cuellar-Camacho JL, Ehrmann S, Chowdhury MS, Zhang M, et al. Multivalent flexible nanogels exhibit broad-spectrum antiviral activity by blocking virus entry. ACS nano. 2018;12(7):6429–42. [220]Leibbrandt A, Meier C, König-Schuster M, Weinmüllner R, KalthoffD, Pflugfelder B, et al. Iota-carrageenan is a potent inhibitor of influenza a virus infection. PLoS One. 2010;5(12):e14320. [221]Buck CB, Thompson CD, Roberts JN, Müller M, Lowy DR, Schiller JT. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006;2(7):e69. [222]Magnan S, Tota J, El-Zein M, Burchell A, Schiller J, Ferenczy A, et al. Efficacy of a carrageenan gel against transmission of cervical HPV (CATCH): Interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial. Clin Microbiol Infect. 2019;25(2):210–6. [223]Zheng M, Qu D, Wang H, Sun Z, Liu X, Chen J, et al. Intranasal administration of chitosan against influenza A (H7N9)virus infection in a mouse model. Sci Rep. 2016;6:28729. 24 Marjan Motiei et al. [224]Kyluik DL, Sutton TC, Le Y, Scott MD. Polymer-mediated broad spectrum antiviral prophylaxis: Utility in high risk environments. Progress in molecular and environmental bioengineering-from analysis and modeling to technology applications. Rijeka: Intech; 2011. p. 167–190. [225]Cai X, Prominski A, Lin Y, Ankenbruck N, Rosenberg J, Chen M, et al. A neutralizing antibody-conjugated photothermal nanoparticle captures and inactivates SARS-CoV-2. biorxiv. 2020. p. 11. [226]Roner MR, Carraher CE, Miller L, Mosca F, Slawek P, Haky JE, et al. Organotin Polymers as Antiviral Agents Including Inhibition of Zika and Vaccinia Viruses. J Inorg Organomet Polym Mater. 2020;30(3):684–94. [227]Motiei M, Kashanian S, Lucia LA, Khazaei M. Intrinsic parameters for the synthesis and tuned properties of amphiphilic chitosan drug delivery nanocarriers. J Controlled Release. 2017;260:213–25. [228]Motiei M, Aboutalebi F, Forouzanfar M, Dormiani K, Nasr- Esfahani MH, Mirahmadi-Zare SZ. Smart co-delivery of miR- 34a and cytotoxic peptides (LTX-315 and melittin)by chitosan based polyelectrolyte nanocarriers for specific cancer cell death induction. Mater Sci Eng C. 2021;128:112258. [229]Nie C, Stadtmüller M, Yang H, Xia Y, WolffT, Cheng C, et al. Spiky nanostructures with geometry-matching topography for virus inhibition. Nano Lett. 2020;20(7):5367–75. [230]Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon III KH, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370(6523):1464–8. [231]Purohit R, Mittal A, Dalela S, Warudkar V, Purohit K, Purohit S. Social, environmental and ethical impacts of nanotechnology. Mater Today Proc. 2017;4(4):5461–7. [232]Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, et al. Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. J Virol. 2020;94(21):e01218–20. [233]Tharayil A, Rajakumari R, Chirayil CJ, Thomas S, Kalarikkal N A short review on nanotechnology interventions against COVID-19. Emergent Mater. 2021;4(1):131–41. SARS-COV-2 and nanotechnology 25